Related Experiment Videos
Stobadine-inhibitor of cyclophosphamide-induced micronuclei in mice
1Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava.
Abstract:
The potential antimutagenic effect of stobadine dipalmitate (STB) on the frequency of micronuclei in reticulocytes of peripheral blood in female ICR mice was studied. The cyclophosphamide model was used to verify this effect. Stobadine dipalmitate was administered orally in three concentrations: STB I, 7.07; STB II, 23.6; STB III, 70.07 mg/kg body wt 2 h prior to or 4 h after (STB II only) cyclophosphamide administration (intraperitoneally, twice 80 mg/kg body wt with a 24 h interval). The method designed by Hayashi et al. [(1990) Mutat. Res., 245, 245-249] was used to prepare and to stain the slides. The results of the experiment show that pretreatment with stobadine 2 h prior to cyclophosphamide administration significantly decreased its mutagenic effect, as manifested by the reduced frequency of micronucleated reticulocytes. This protective effect of stobadine was concentration-dependent with the highest concentration of stobadine inducing the most pronounced decrease of micronuclei. Analysis and identification of the exact mechanism of the protective effects of stobadine is the aim of our further studies.
Insights
Stobadine dipalmitate (STB) demonstrated antimutagenic properties by reducing cyclophosphamide-induced micronuclei in mice. This protective effect was dose-dependent, highlighting STB
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Cyclophosphamide is a known mutagen.
- Assessing antimutagenic compounds is crucial for developing protective agents.
- Micronuclei in reticulocytes serve as a biomarker for genotoxicity.
Purpose of the Study:
- To evaluate the potential antimutagenic effect of stobadine dipalmitate (STB).
- To investigate the dose-response relationship of STB's protective effect against cyclophosphamide-induced mutagenicity.
Main Methods:
- Utilized the cyclophosphamide model in female ICR mice.
- Administered stobadine dipalmitate orally at varying concentrations (7.07, 23.6, 70.07 mg/kg).
- Prepared and stained peripheral blood slides using the Hayashi et al. method to assess micronucleated reticulocytes.
Main Results:
- Pretreatment with stobadine dipalmitate significantly reduced the mutagenic effect of cyclophosphamide.
- A concentration-dependent reduction in micronucleated reticulocytes was observed.
- The highest concentration of stobadine dipalmitate exhibited the most significant decrease in micronuclei.
Conclusions:
- Stobadine dipalmitate exhibits significant antimutagenic activity.
- The protective effect is concentration-dependent.
- Further research is needed to elucidate the precise mechanism of action.